• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Reducing Low-Value Care May Mean Tough Conversations With Stakeholders

Article

The concept of value is a well-known topic among health policy experts, the payer community, and policy makers, but patients do not necessarily have the same idea of what value means. When discussions about removing low-value care from the system to save money come up, patients might get the wrong idea of what is going on and why.

Reducing low-value care can free up money to be spent on high-value services, but it’s a delicate conversation to have, according to panelists at the University of Michigan Center for Value-Based Insurance Design (V-BID)’s V-BID Summit, held March 13 in Ann Arbor, Michigan.

The concept of value is a well-known topic among health policy experts, the payer community, and policy makers, but patients do not necessarily have the same idea of what value means, explained Daniel Carey, MD, secretary of health and human services for the Commonwealth of Virginia.

For instance, when the concept of value is introduced into a conversation around achieving access to care, some stakeholders might get the wrong idea, he said.

“For some, I found out in the last 6 or 8 months, that sounds like we’re trying to reduce access…trying to take something away,” Carey explained.

The language being used in these discussions is crucial, said Gwen Darien, executive vice president for patient advocacy and engagement at the National Patient Advocate Foundation (NPAF). Her organization represents approximately 150,000 patients who are primarily low-income, underresourced, and have trouble accessing quality, affordable, and equitable care.

Patients don’t think about the mathematical formula policy makers and other experts in the field are using to define value and remove services that are considered low-value because they might cause harm or be unnecessary. Instead, patients are concerned with a notion ingrained in American culture that if something is being taken away from them, then they’re being stinted.

The conversation has to make it clear that services are being taken away in order to keep patients safe from harm, she added.

“A lot of the ways that we’ve talked about reducing low-value services has had to do with waste and waste in the system,” Darien said. “People do not want to hear that anything that their doctor is prescribing for them is wasteful.”

That’s why explaining the harm of unnecessary or low-value services is important and can help the patient understand that the concern is keeping them safe.

“Less can often be more, because more can lead to unintended consequences,” she added.

When Cigna talks about reducing low-value services, many times people interpret that as taking away care, according to John Keats, MD, national medical director for affordability and specialty partnerships at Cigna. But the company tries to be very deliberate and uses evidence generated by other organizations and the recommendations of the United States Preventive Services Task Force (USPSTF) to make decisions on low-value care that can be removed. If USPSTF gives something a D rating, which means it is not recommended to be used in asymptomatic patients.

One of the services the panelists gave as an example of a low-value service that is used a lot and can be cut out of the system is vitamin D screening. Cigna defined a population where vitamin D screening was recommended and for any patients who didn’t meet that criteria, it would not pay for the test. According to Keats, a year later, doctors have stopped ordering the test and it has saved $20 million.

“This whole idea of low-value care, I think, is great, but what I see time and again [is]…we have to be on the lookout for low-value physicians,” Keats said. “At the end of the day, this is physician driven.”

Beth Bortz, president and chief executive officer of the Virginia Center for Health Innovation (VCHI), was in the audience and mentioned that some physicians don’t even realize they’re ordering the test as often as they are. She related the story of a member of USPSTF whom VCHI was working with in its quest to identify and measure uses of low-value care, who saw his data on vitamin D screening and thought it must have been wrong because he would never order that many vitamin D screenings. But once he dug into the data, he realized that a vitamin D screening was part of a bundled lab, and he was ordering it far more than he realized.

“I think that’s a big piece of the secret sauce [to reducing use of low-value services],” Bortz said. “They have to sit with [the data], look at it, dig into it.”

Carey admitted that there is pushback even from physicians when it comes removing low-value care, and it’s not because they don’t think low-value care utilization isn’t an issue. Most physicians agree with the concept of removing low-value care, but they worry it will be overinterpreted and that the 5% or 10% who do need the service will miss out on it. The pushback, he clarified, has been on an “inflexible system” that doesn’t allow leeway for someone to step off and provide services that might be low-value for the majority of people but fit for that specific patient.

All this work to remove low-value care can have real benefits for patients, as it saves money that might have been used on unnecessary services and frees those dollars up for high-quality services to be used. Darien used the example of lung cancer, where if money is freed up, everyone can get their tumor sequenced so they are given the right treatment that will work for them instead of being treated “scattershot.”

“That’s removing low-value care to add high-value care,” she said.

In Virginia, VCHI just received $2.2 million to launch a 3-year statewide pilot to reduce the use of low-value care. The pilot will bring together 6 health systems and 3 clinically integrated networks to form a large-scale health system learning community and also create an employer task force that includes employers, the Virginia Chamber of Commerce, and the Virginia Business Coalition. This is the next step after the work Virginia has done to identify and measure low-value care utilization.

“Once we’ve moved the dial, then we’ll explore the headroom,” Carey said. “We need to turn waste into real dollars.”

Related Videos
Shawn Kwatra, MD, dermatologist, John Hopkins University
Dr Laura Ferris Discusses Safety, Efficacy of JNJ-2113 in Patients with Plaque Psoriasis
dr krystyn van vliet
Martin Dahl, PhD, senior vice president, AnaptysBio
Jeff Stark, MD, vice president, head of medical immunology, UCB.
Jonathan Silverberg, MD, PhD, MPH, FAAD, professor of dermatology, director of clinical research and patch testing, George Washington University School of Medicine and Health Sciences
Monica Li, MD, University of British Columbia
Robert Sidbury, MD, MPH, FAAD, professor of pediatrics, division head of dermatology, Seattle Children's Hospital, University of Washington School of Medicine
Raj Chovatiya, MD, PhD, associate professor at the Rosalind Franklin University Chicago Medical School, founder and director of the Center for Medical Dermatology and Immunology Research
Amy S. Paller, MD, Chair of Dermatology, Feinberg School of Medicine, Northwestern University
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.